Cargando…
Reversible inhibition of lysine specific demethylase 1 is a novel anti-tumor strategy for poorly differentiated endometrial carcinoma
BACKGROUND: Endometrial cancer is the most common gynecologic malignancy. Type II endometrial carcinoma is often poorly differentiated and patients diagnosed with Type II disease (~11%) are disproportionately represented in annual endometrial cancer deaths (48%). Recent genomic studies highlight mut...
Autores principales: | Theisen, Emily R, Gajiwala, Snehal, Bearss, Jared, Sorna, Venkataswamy, Sharma, Sunil, Janat-Amsbury, Margit |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4197342/ https://www.ncbi.nlm.nih.gov/pubmed/25300887 http://dx.doi.org/10.1186/1471-2407-14-752 |
Ejemplares similares
-
Lysine specific demethylase 1 is a molecular driver and therapeutic target in sarcoma
por: Dreher, Rachel D., et al.
Publicado: (2023) -
Chromatin profiling reveals relocalization of lysine-specific demethylase 1 by an oncogenic fusion protein
por: Theisen, Emily R., et al.
Publicado: (2020) -
An estrogen-induced endometrial hyperplasia mouse model recapitulating human disease progression and genetic aberrations
por: Yang, Chieh-Hsiang, et al.
Publicado: (2015) -
Chemical Biology of Lysine Demethylases
por: Heightman, Tom D
Publicado: (2011) -
Histone demethylase lysine demethylase 5B in development and cancer
por: Han, Mengjiao, et al.
Publicado: (2016)